AACR 2024 | Should radioligand therapies be used in earlier settings in prostate cancer?

Andres Ricaurte-Fajardo, MD, Weill Cornell Medicine, New York, NY, comments on the possibility of using radioligand therapies in earlier stages of prostate cancer, which are currently administered in patients with metastatic castration-resistant prostate cancer (mCRPC). Radioligands have been very promising in pretreated patients, especially in those who progressed on androgen-receptor signaling inhibitors (ARSI), and studies are underway to assess radioligands in earlier lines of therapy.. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.